世界のメタボロミクス（メタボローム解析）市場（～2019）：技術、用途別分析...市場調査レポートについてご紹介

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size Estimation
1.5.2 Market crackdown and Data Triangulation
1.5.3 Market Forecasting Model
1.5.4 Key Data Point Taken from Secondary Sources
1.5.5 Key Data Point Taken from Primary Sources

2 Executive Summary

3 Premium Insights

4 Technology Investment Potential
4.1 Introduction
4.2 Investment Client Networks
4.3 Funding Bodies
4.4 Funding Opportunities
4.5 Analysis of Potential Areas for Technology Investment using Strategic Evaluation
4.5.1 Parameters Considered for Emerging Opportunity Evaluation
4.5.2 Opportunity Strategic Evaluation Analysis
4.5.3 Description of Opportunities

5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Research Funding and government support spurs the growth of this market
5.3.1.2 Biotechnology & Pharmaceutical Sectors Drive Metabolomics Research
5.3.1.3 Increasing demand for personalized medicine in healthcare industry
5.3.1.4 Increased Necessity for Toxicity Technologies
5.3.2 Restrains
5.3.2.1 Complexity in Data Processing & Analysis
5.3.2.2 Low Adoption Rate of Metabolomics Technologies
5.3.3 Opportunities
5.3.3.1 Untapped Emerging Market
5.3.3.2 Biomarker Discovery Services
5.3.4 Trends
5.3.4.1 Technological Advancements
5.3.4.2 Collaborations Between Research Universities and Market Players

6 Market Share Analysis

7 —  Metabolomics Market, by Technique
7.1 Introduction
7.2 Separation Techniques
7.2.1 Gas Chromatography (GC)
7.2.2 Ultra Performance Liquid Chromatography (UPLC)
7.2.3 High Performance Liquid Chromatography (HPLC)
7.2.4 Capillary Electrophoresis (CE)
7.3 Detection Techniques
7.3.1 Mass Spectrometry (MS)
7.3.2 Nuclear Magnetic Resonance Spectroscopy (NMR)
7.3.3 Surface Based Mass Analysis

8 —  Metabolomics Market, by Application
8.1 Introduction
8.2 Biomarker Discovery
8.3 Drug Discovery/Drug Assessment
8.4 Toxicity Assessment/Toxicology
8.5 Nutrigenomics
8.6 Others

9 —  Metabolomics Market, by Indication
9.1 Introduction
9.2 Oncology
9.3 Cardiology
9.4 Neurology
9.5 Others

10 —  Metabolomics Market, by Geography
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 U.K.
10.3.2 Germany
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 RoE
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 RoA
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.2 Latin America

11 Competitive Landscape
11.1 Introduction
11.2 New Product Launches
11.3 Expansions
11.4 Acquisitions
11.5 Agreements, Partnerships, and Collaborations
11.6 Product Enhancements

12 Company Profiles
12.1 Agilent Technologies
12.2 Biocrates Life Sciences AG
12.3 Bruker Corporation
12.4 Danaher Corporation
12.5 Human Metabolomics Technologies, Inc.
12.6 LECO Corporation
12.7 Metabolon, Inc.
12.8 Shimadzu Corporation
12.9 Thermo Fisher Scientific, Inc.
12.10 Waters Corporation

13 Appendix